Physician profile
Melissa R Diloreto
NPI 1851670913
$4,238.60
in general payments reported to CMS, 2019-2025
37 companies · $1,010 in 2025
The $1,010 reported for 2025 was more than what 97% of Obstetrics & Gynecology (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $324 · 2022: $1,041 · 2023: $1,014 · 2024: $850 · 2025: $1,010.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,582 · Education: $293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,581.54 |
| Education | $292.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $660.19 | 2021-2025 | |
| Astellas Pharma US INC | $419.27 | 2022-2025 | Veozah, Myrbetriq |
| Exeltis, USA INC. | $355.06 | 2021-2025 | Slynd |
| Sumitomo Pharma America, INC. | $282.70 | 2023-2025 | Myfembree, Gemtesa |
| Agile Therapeutics, INC. | $259.97 | 2022-2024 | Twirla |
| Mayne Pharma Commercial LLC | $252.52 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $247.13 | 2021-2025 | Gardasil 9, Gardasil, Capvaxive |
| Myovant Sciences INC. | $198.61 | 2021-2022 | |
| Pfizer INC. | $185.42 | 2022-2025 | |
| Millicent US INC | $158.79 | 2024-2025 | Femlyv, Intrarosa, Femring |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $153.92 | 2021-2025 | Xifaxan |
| Lilly USA, LLC | $152.01 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Sage Therapeutics, LLC | $139.80 | 2024-2025 | Zurzuvae |
| Evofem Biosciences, INC. | $102.24 | 2022 | |
| Therapeuticsmd, INC. | $85.58 | 2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $73.39 | 2025 | Rexulti |
| Organon LLC | $64.04 | 2022-2024 | Nexplanon |
| Exact Sciences Corporation | $62.62 | 2025 | Cologuard Collection Kit |
| Amgen INC. | $38.93 | 2023-2025 | Repatha, Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $26.58 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.15 | 2021 | |
| Novo Nordisk INC | $24.13 | 2025 | |
| Axsome Therapeutics, INC. | $22.27 | 2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $21.18 | 2025 | Qelbree |
| Coopersurgical, INC. | $20.09 | 2024 | Paragard T 380a |
| Axonics, INC. | $19.78 | 2024 | Axonics |
| Astrazeneca Pharmaceuticals Lp | $19.70 | 2025 | Breztri |
| Upsher-Smith Laboratories LLC | $19.57 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.05 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.98 | 2021 | |
| Baxter Healthcare | $17.99 | 2022 | |
| Scynexis, INC. | $17.27 | 2022 | |
| Almatica Pharma LLC | $16.21 | 2022 | |
| Redhill Biopharma INC. | $15.66 | 2021 | |
| Welch Allyn | $15.42 | 2021 | |
| Avion Pharmaceuticals | $14.85 | 2021 | |
| Lupin INC. | $13.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Diloreto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.